Ekso Bionics price target raised to $6 from $4 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Ekso Bionics (EKSO) to $6 from $4 and keeps a Buy rating on the shares. The company reported a solid Q3 report and announced it has initiated a strategic review of the current business, the analyst tells investors in a research note. The firm does not account for any transaction at this time. Ekso’s sales recovery in Q3 implies that order delays from the prior quarter “appear to be idiosyncratic,” but it remains to be seen if this trend can continue, contends H.C. Wainwright.